KHAN Technology Transfer Fund
- Company typePrivate
- Founded2019
- HeadquartersDortmund, Germany
- Headcount1–10
- GTM typeB2B
- OfferingServices
KHAN Technology Transfer Fund firmographics
Firmographics- Name
- KHAN Technology Transfer Fund
- Legal name
- KHAN Technology Transfer Fund
- Website
- https://khanu.de
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
KHAN Technology Transfer Fund industry classification
Industry- Product category
- Life Sciences Venture Capital
- NAICS
- Other Investment Pools and Funds (5259), Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (525990)
- SIC
- Investment Advice (6282), Patent Owners & Lessors (6794)
- akta.pro primary industry
- Late-Stage Venture Capital (Series C+) (FSANAAAC)
Keywords
Where KHAN Technology Transfer Fund is headquartered
LocationHeadquarters
- HQ city
- Dortmund
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
KHAN Technology Transfer Fund business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Others
Revenue model
- Fund Management: KHAN operates as a venture capital fund generating returns through management fees and carried interest from successful portfolio companies. The fund invests in early-stage life sciences companies and creates value through cooperative drug development partnerships.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
KHAN Technology Transfer Fund product offering
Product offeringCore offering
KHAN Technology Transfer Fund is an early-stage life sciences venture capital fund that invests in academic drug discovery assets through direct equity investments, convertible loans, and scientific asset financing. The fund operates an active facilitator/incubator model in partnership with Lead Discovery Center GmbH (LDC), providing project structuring, lean virtual company building, IP rights ownership, and commercialization services to translate first-in-class academic projects into investable biotech companies addressing high unmet medical need.
Product overview
KHAN Technology Transfer Fund is an early-stage life sciences venture fund that creates value through cooperative drug development partnerships with academic innovators in Europe. The fund focuses on first-in-class therapies for attractive markets with high unmet medical need. KHAN operates through a unique ecosystem in partnership with Lead Discovery Center GmbH (LDC), providing funding, structuring, and incubation services to translate academic science into commercially viable drug assets. The fund manages KHAN-I (€70 million) and KHAN-II (>€51 million first closing, targeting €100 million total), investing in scientific assets, equity, and convertible loans at proof of concept, pre-seed, and seed stages.
Differentiator
Problem solved
Functional benefit
Products and services
- KHAN Technology Transfer Fund I (KHAN-I) Early-stage life sciences venture capital fund providing equity investments, convertible loans, and scientific asset financing to first-in-class drug discovery projects, primarily sourced from European academic institutions. Targets proof-of-concept through pre-seed and seed stage investments, with active incubation support via Lead Discovery Center GmbH partnership.
- KHAN Technology Transfer Fund II (KHAN-II) Follow-on early-stage life sciences venture capital fund with first closing of €51 million and a €100 million target. Provides the same equity, convertible loan, and scientific asset financing instruments as KHAN-I, alongside an additional EUR 18 million co-investment agreement with the Max Planck Society for joint 50:50 funding of drug discovery projects from Max Planck Institutes.
- Incubation and Facilitation Services Active facilitator/incubator offering for portfolio companies that does not require fully validated assets, filed patents, legal entities, or complete teams. Services include project structuring, lean (semi) virtual company building, integration of academic innovators while keeping them in their academic environments, flexible funding provision, IP rights ownership for KHAN-financed projects, and commercialization pathways to pharma and biotech.
Quantifiable outcome
- Over 50 scientific assets funded
- +3 more outcomes
Companies that use KHAN Technology Transfer Fund
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles2 records
KHAN Technology Transfer Fund technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
KHAN Technology Transfer Fund partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- HLB Life Science R&DminorLicensed next-generation anticancer drug candidate from LDC/KHAN-I for co-development. HLB has exclusive worldwide rights and will move candidate into clinical development with LDC.
- Lead Discovery Center GmbH (LDC)coreLDC is a fully operational drug discovery incubator with state-of-the-art services and established academic/industrial network. KHAN operates in close partnership with LDC in Dortmund and Munich to close the gap in translating science into products.
- Max Planck SocietycoreKHAN has a preferred partnership agreement with Max Planck Society to jointly invest in translation of promising early-stage academic projects in drug discovery from Max Planck Institutes. Both MPG and KHAN co-fund MPG projects on a 50:50 basis.
- Lead Discovery Center Partner NetworkminorLDC has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, invIOs, Novo Nordisk, Cumulus Oncology, Nodus Oncology, JT Pharmaceuticals, KinSea, and Helmholtz Centre for Infection Research.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
KHAN Technology Transfer Fund competitors and assessment
Company assessmentDirect peers
- BioGeneration Ventures (BGV): Amsterdam-based early-stage European biotech VC fund focused on pre-seed/seed and Series A in life sciences, founded 2006. Closest peer given its similar European, early-stage, first-in-class technology investment focus and university-spinout sourcing model.
- Forbion: Leading European life sciences VC managing >€3B AUM across multiple funds focused on biotech therapeutics, including early-stage and growth opportunities comparable to KHAN's investment stages and European academic sourcing.
- Life Science Partners (LSP): Dutch-based life sciences-dedicated VC investing across early and growth stages in therapeutics, with comparable European academic spin-out sourcing and active company-building approach.
- Omega Funds: Boston-based but transatlantic life sciences-dedicated VC investing across public and private healthcare. Similar first-in-class therapeutic focus and overlapping LPs (EIF and institutional investors) make it a comparable peer.
- Medicxi: London-based life sciences VC focusing on early-stage drug discovery and asset-centric companies, often sourced from pharma spinouts and academia — directly comparable operating model to KHAN's tech-transfer and incubator-led investing.
- Syncona: UK-based life sciences investment company building and owning biotech companies founded on academic and clinical research — analogous technology transfer/asset-creation model in European life sciences.
- Kurma Partners: Paris-based European healthcare and life sciences VC investing across early-stage therapeutics and digital health. Lead investor on KHAN portfolio company EvlaBio's €21M seed, demonstrating directly overlapping deal activity in European biotech seeds.
- Andera Partners: Paris-based VC firm (formerly Edmond de Rothschild) with dedicated life sciences franchise investing from pre-seed through growth in European biotech — comparable in fund size range and therapeutic focus.
- Novo Seeds: Copenhagen-based early-stage biotech VC within the Novo Holdings ecosystem, investing pre-seed and seed in Nordic/European life sciences — comparable thesis on academic-originated first-in-class therapeutic assets.
- Apollo Therapeutics: UK-based biotech venture fund backed by AstraZeneca, GSK, Johnson & Johnson, and the Wellcome Trust — investing in first-in-class therapeutics from leading UK/European university research. Most comparable given direct pharma-LP sourcing from top-tier pharma partners.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
KHAN Technology Transfer Fund social profiles
Digital presenceKHAN Technology Transfer Fund financial estimates
Financial estimateRevenue estimate
Valuation estimate
KHAN Technology Transfer Fund leadership team
Management profileNumber of profiles
Profiles7 records
KHAN Technology Transfer Fund funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
KHAN Technology Transfer Fund M&A and investment
M&A and investmentM&A
Investments12 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about KHAN Technology Transfer Fund
What does KHAN Technology Transfer Fund do?
KHAN Technology Transfer Fund is an early-stage life sciences venture capital fund that invests in academic drug discovery assets through direct equity investments, convertible loans, and scientific asset financing. The fund operates an active facilitator/incubator model in partnership with Lead Discovery Center GmbH (LDC), providing project structuring, lean virtual company building, IP rights ownership, and commercialization services to translate first-in-class academic projects into investable biotech companies addressing high unmet medical need.
Is KHAN Technology Transfer Fund a public or private company?
KHAN Technology Transfer Fund is a private company. It is classified as management employee owned and is currently operating.
When was KHAN Technology Transfer Fund founded?
KHAN Technology Transfer Fund was founded in 2019. It employs 1 to 10 people.
Where is KHAN Technology Transfer Fund based?
KHAN Technology Transfer Fund is headquartered in Dortmund, Germany, in the Europe region.
How does KHAN Technology Transfer Fund make money?
One revenue line is on record: fund Management.
Who are KHAN Technology Transfer Fund's main competitors?
Direct peers on record are BioGeneration Ventures (BGV), Forbion, Life Science Partners (LSP), Omega Funds, Medicxi, Syncona, Kurma Partners, Andera Partners, Novo Seeds and Apollo Therapeutics.
Does KHAN Technology Transfer Fund have an API?
No public API is recorded for KHAN Technology Transfer Fund.
What industry is KHAN Technology Transfer Fund in?
KHAN Technology Transfer Fund's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAAAC, Late-Stage Venture Capital (Series C+). Its NAICS code is 5259 and its SIC code is 6282.